The Administrative Core will provide management services to each of the Projects and Cores in this Program. The Core will provide financial, administrative, and clerical services for the PI, the Co-Pl, Project Leaders, and Core Leaders for all grant-related activities. These activities include preparation of this competing renewal, non-competing renewals including progress reports, preparation of budgets, communication with the NIH regarding renewals and all financial interactions, and assurance that the labs supported by this Program are in full compliance with all institutional, state and federal regulations. Core A will also coordinate and schedule all meetings related to the function of the Program, including monthly meetings of all Project and Core leaders, and members of their respective laboratories, as well as annual meetings of the Internal and External Advisory Boards. Core A will also coordinate efforts with Dr. Armstrong, the sole off-site investigator, to travel to meetings or teleconference. Dr. Ebert is the PI and Director of this Core, and will serve as the overall scientific director and chief administrator. Dr. Griffin is the Co-Pl and will assist in these operations, particularly with regard to clinical programs, core facilities, and samples at the DFCI. He will assist Dr. Ebert in monitoring protocol performance and will assist in protocol development. Chanel Logan is a highly skilled administrator with experience in management of fiscal and administrative matters for large program project grants. She will serve as Administrative Facilitator, manage budgets between participating institutions, prepare reports including non-competing renewals, interface with the financial officers of each participating institution in the Program, and serve as an interface between these groups and the NIH. In addition, the Administrative Core will assure compliance and appropriate regulations regarding experimentation with human subjects, (including gender and minority participation) and vertebrate animals.

Public Health Relevance

The Administrative Core will provide management services to each of the Projects and Cores in this Program. The Core will provide financial, administrative, and clerical services for the Pl, the Co-Pl, Project Leaders, and Core Leaders for all grant-related activities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA066996-20
Application #
9556988
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2018-09-01
Budget End
2019-08-31
Support Year
20
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
Hogan, Louise E; Körner, Christian; Hobbs, Kristen et al. (2018) NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. Blood Adv 2:1412-1416
Kelly, Rachel S; Lasky-Su, Jessica; Yeung, Sai-Ching J et al. (2018) Integrative omics to detect bacteremia in patients with febrile neutropenia. PLoS One 13:e0197049
Nakamura, Makoto; Wu, Lizi; Griffin, James D et al. (2018) Notch1 activation enhances proliferation via activation of cdc2 and delays differentiation of myeloid progenitors. Leuk Res 72:34-44
Gechijian, Lara N; Buckley, Dennis L; Lawlor, Matthew A et al. (2018) Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nat Chem Biol 14:405-412
Sridhar, Radhakrishnan; Takei, Hisashi; Syed, Riyaz et al. (2018) Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBP?. Molecules 23:
Chu, S Haihua; Song, Evelyn J; Chabon, Jonathan R et al. (2018) Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras. Blood Adv 2:2478-2490
Wang, Jinhua; Erazo, Tatiana; Ferguson, Fleur M et al. (2018) Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. ACS Chem Biol 13:2438-2448
Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303
Cortes, Jorge E; Douglas Smith, B; Wang, Eunice S et al. (2018) Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol 93:1301-1310
Fathi, Amir T; Erba, Harry P; Lancet, Jeffrey E et al. (2018) A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood 132:1125-1133

Showing the most recent 10 out of 376 publications